EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Position Lifted by Federated Hermes Inc.

Federated Hermes Inc. grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 194.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 674,824 shares of the company’s stock after acquiring an additional 445,289 shares during the quarter. Federated Hermes Inc. owned approximately 1.43% of EyePoint Pharmaceuticals worth $15,595,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in EYPT. Barclays PLC increased its stake in EyePoint Pharmaceuticals by 103.4% during the third quarter. Barclays PLC now owns 45,659 shares of the company’s stock valued at $365,000 after purchasing an additional 23,208 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at about $574,000. Scotia Capital Inc. raised its stake in EyePoint Pharmaceuticals by 144.9% during the third quarter. Scotia Capital Inc. now owns 90,963 shares of the company’s stock worth $727,000 after acquiring an additional 53,820 shares during the period. DekaBank Deutsche Girozentrale bought a new position in EyePoint Pharmaceuticals in the fourth quarter worth about $820,000. Finally, Jump Financial LLC boosted its stake in EyePoint Pharmaceuticals by 318.5% in the third quarter. Jump Financial LLC now owns 48,968 shares of the company’s stock valued at $391,000 after acquiring an additional 37,268 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Mizuho increased their price target on EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. JPMorgan Chase & Co. assumed coverage on EyePoint Pharmaceuticals in a research note on Monday, January 22nd. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright lowered their price target on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, January 16th. Finally, Capital One Financial reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.00.

EyePoint Pharmaceuticals Stock Down 4.0 %

EYPT stock opened at $16.95 on Tuesday. The company has a 50-day simple moving average of $23.43 and a 200 day simple moving average of $18.54. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $5.67 and a fifty-two week high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The company had revenue of $14.03 million during the quarter, compared to analyst estimates of $8.71 million. During the same period in the prior year, the business posted ($0.61) EPS. On average, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -1.73 EPS for the current year.

Insider Buying and Selling at EyePoint Pharmaceuticals

In other news, insider Dario A. Paggiarino sold 49,325 shares of the business’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $25.66, for a total value of $1,265,679.50. Following the sale, the insider now owns 36,505 shares of the company’s stock, valued at approximately $936,718.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other EyePoint Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp bought 581,765 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Thursday, April 18th. The stock was purchased at an average cost of $18.03 per share, for a total transaction of $10,489,222.95. Following the completion of the acquisition, the insider now owns 7,475,000 shares of the company’s stock, valued at approximately $134,774,250. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Dario A. Paggiarino sold 49,325 shares of the company’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $25.66, for a total value of $1,265,679.50. Following the completion of the transaction, the insider now directly owns 36,505 shares in the company, valued at approximately $936,718.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,134 shares of company stock valued at $1,286,634. 13.05% of the stock is owned by corporate insiders.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.